Crosstalk of methylation and tamoxifen in breast cancer (Review).
Mol Med Rep
; 30(4)2024 Oct.
Article
in En
| MEDLINE
| ID: mdl-39129315
ABSTRACT
Tamoxifen is a widely used antiestrogen drug in the endocrine therapy of breast cancer (BC). It blocks estrogen signaling by competitively binding to estrogen receptor α (ERα), thereby inhibiting the growth of BC cells. However, with the longterm application of tamoxifen, a subset of patients with BC have shown resistance to tamoxifen, which leads to low overall survival and progressionfree survival. The molecular mechanism of resistance is mainly due to downregulation of ERα expression and abnormal activation of the PI3K/AKT/mTOR signaling pathway. Moreover, the downregulation of targeted gene expression mediated by DNA methylation is an important regulatory mode to control protein expression. In the present review, methylation and tamoxifen are briefly introduced, followed by a focus on the effect of methylation on tamoxifen resistance and sensitivity. Finally, the clinical application of methylation for tamoxifen is described, including its use as a prognostic indicator. Finally, it is hypothesized that when methylation is used in combination with tamoxifen, it could recover the resistance of tamoxifen.
Key words
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Tamoxifen
/
Breast Neoplasms
/
Drug Resistance, Neoplasm
/
DNA Methylation
Limits:
Female
/
Humans
Language:
En
Journal:
Mol Med Rep
Year:
2024
Document type:
Article
Country of publication:
Greece